Abstract: A method for treating hematologic malignancies comprises administration of a composition inclusive of 64Zne(Asp) in a therapeutically effective amount. Such administration may be via intravenous injection and/or infusion and may be once a day or more than once a day. Other identified compounds may be bound to 64Zne replacing L-Aspartate (Asp), provided that the resulting molecular weight does not exceed 700 Da and the resulting compound nanoparticles are less than 50.5 nm in size. The composition is suitable for intravenous injection and/or infusion.

Abstract: A method for treating carcinoma and sarcoma tumors includes administration of a composition including 64Zne(Asp) or 63Cue(Asp) in a therapeutically effective amount. The method may be used once a day or more than once a day. Other identified amino acids may be bound to 64Zne and 63Cue instead of L-Aspartate (Asp), provided that such amino acids are enriched for the L-enantiomer to at least 90%. The composition is suitable for a parenteral injection or infusion. The method may be used for suppressing growth of carcinoma and sarcoma, including preventing the development of metastases.

Abstract: A method for treating hematologic malignancies comprises administration of a composition inclusive of 64Zne(Asp) in a therapeutically effective amount. Such administration may be via intravenous injection and/or infusion and may be once a day or more than once a day. Other identified compounds may be bound to 64Zne replacing L-Aspartate (Asp), provided that the resulting molecular weight does not exceed 700 Da and the resulting compound nanoparticles are less than 50.5 nm in size. The composition is suitable for intravenous injection and/or infusion.

Abstract: A method of treating cancer or cancer metastasis comprising administering to a patient in need thereof a therapeutically effective amount of one or more anticancer agent selected from the group consisting of chemotherapy, an immunotherapy, a kinase inhibitor, a monoclonal antibody, and an antibody-drug conjugate, and at least one isotope selective modulator inclusive of at least one isotope selected from the group consisting of 63Cu, 64Zn, 66Zn, and 85Rb, wherein said isotope is enriched to exceed 99% atomic mass.

Abstract: A pharmaceutical composition for isotope-selective modulation including at least one isotope selected from the group consisting of 1H, 6Li, 12C, 10B, 14N, 16O, 17O, 24 Mg, 26 Mg, 28Si, 29Si, 32S, 33S, 39K, 35Cl, 40Ca, 42Ca, 43Ca, 50V, 50Cr, 52Cr, 54Fe, 56Fe, 58Ni, 60Ni, 61Ni, 63Cu, 64Zn, 66Zn, 92Mo, 94Mo, 95Mo, 96Mo, 74Se, 76Se, 77Se, 78Se, 70Ge, 72Ge, 73Ge, 79Br, 85Rb, 107 Ag, 130Ba, 132Ba, 134Ba, 135Ba, and 136Ba, wherein said at least one selected isotope is enriched to exceed its relative isotopic ratio found in a naturally occurring sample of the same chemical element. Methods for its use include investigating the isotopic signatures, intervening with isotopic fractionation in mammals.

Abstract: A pharmaceutical composition is used for improving health, curing abnormalities and degenerative diseases, and achieving anti-aging therapeutic effect in mammals. The pharmaceutical composition includes a pharmaceutical carrier and an isotope selective component including at least one of a chemical element in which the isotopic ratio of at least one light isotope is altered to exceed natural abundance.

Abstract: Disclosed are therapeutic compositions of matter for use in regulation of local and systemic inflammation and reduction of oxidative stress to enable discovery and development of more effective pharmaceutical agents, organic compounds, and other medicinal formulations.

Abstract: A method for treating melanoma or preventing the development of melanoma comprising administration of a composition comprising 64Zne(Asp)2 in a therapeutically effective amount. Such administration may be via injection such as intratumoral and/or intravenous injection and may be once a day or more than once a day. A composition for the treatment of or prevention of melanoma comprising 64Zne(Asp)2 in a therapeutically effective amount. The composition may be a liquid suitable for injection.

Abstract: A pharmaceutical composition is used for improving health, curing abnormalities and degenerative diseases, and achieving anti-aging therapeutic effect in mammals. The novel pharmaceutical composition includes a pharmaceutical carrier and an isotope selective component including at least one of a chemical element in which the isotopic ratio of at least one light isotope is altered to exceed natural abundance.

Abstract: A pharmaceutical composition is used for improving health, curing abnormalities and degenerative diseases, and achieving anti-aging therapeutic effect in mammals. The pharmaceutical composition includes a pharmaceutical carrier and an isotope selective component including at least one of a chemical element in which the isotopic ratio of at least one light isotope is altered to exceed natural abundance.

Abstract: Compositions that comprise salts, compounds and complexes of 64Zn-enriched zinc, such as 64Zn-enriched zinc aspartate, and further optionally include 85Rb-enriched rubidium salt compounds of general formula 1, below, wherein each of R1 through R14 is independently selected from H, OH, F, Cl, Br, I, C1-C6 alkyl, C1-C6 alkoxy, and NO2, such as the compound of Formula 1 in which R3 is CH3 and all other R groups are H for use to treat a neurodegenerative disease (NDD), such as Parkinson's disease (PD). Methods that entail administering such compositions to treat an NDD, such as PD, optionally in combination with any other treatment for an NDD such as for PD.

Abstract: A method for treating melanoma or preventing the development of melanoma comprising administration of a composition comprising 64Zne(Asp)2 in a therapeutically effective amount. Such administration may be via injection such as intratumoral and/or intravenous injection and may be once a day or more than once a day. A composition for the treatment of or prevention of melanoma comprising 64Zne(Asp)2 in a therapeutically effective amount. The composition may be a liquid suitable for injection.

Abstract: Compositions that comprise salts, compounds and complexes of 64Zn-enriched zinc, such as 64Zn-enriched zinc aspartate, and further optionally include 85Rb-enriched rubidium salt compounds of general formula 1, below, wherein each of R1 through R14 is independently selected from H, OH, F, Cl, Br, I, C1-C6 alkyl, C1-C6 alkoxy, and NO2, such as the compound of Formula 1 in which R3 is CH3 and all other R groups are H for use to treat a neurodegenerative disease (NDD), such as Parkinson's disease (PD). Methods that entail administering such compositions to treat an NDD, such as PD, optionally in combination with any other treatment for an NDD such as for PD.

Abstract: A method for treating melanoma or preventing the development of melanoma comprising administration of a composition comprising 64Zne(Asp)2 in a therapeutically effective amount. Such administration may be via injection such as intratumoral and/or intravenous injection and may be once a day or more than once a day. A composition for the treatment of or prevention of melanoma comprising 64Zne(Asp)2 in a therapeutically effective amount. The composition may be a liquid suitable for injection.

Abstract: A method for treating melanoma or preventing the development of melanoma comprising administration of a composition comprising 64Zne(Asp)2 in a therapeutically effective amount. Such administration may be via injection such as intratumoral and/or intravenous injection and may be once a day or more than once a day. A composition for the treatment of or prevention of melanoma comprising 64Zne(Asp)2 in a therapeutically effective amount. The composition may be a liquid suitable for injection.